Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
$0.06
$0.07
$0.00
$0.12
$18.29M1.7766,422 shs138,416 shs
Immune Pharmaceuticals, Inc. stock logo
IMNPQ
Immune Pharmaceuticals
$0.00
$0.00
$0.00
$0.01
N/AN/AN/AN/A
EOM Pharmaceuticals Holdings, Inc. stock logo
IMUC
EOM Pharmaceuticals
$0.20
$0.22
$0.11
$0.40
N/A0.373,338 shsN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$3.00
$1.50
$19.37
$7.07M2.899,592 shs4,300 shs
NSPX
Inspyr Therapeutics
$0.00
$0.00
$0.07
$1.47M-17.3313.19 million shs29.64 million shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
0.00%-13.24%-10.61%-26.25%+84.38%
Immune Pharmaceuticals, Inc. stock logo
IMNPQ
Immune Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
EOM Pharmaceuticals Holdings, Inc. stock logo
IMUC
EOM Pharmaceuticals
0.00%+12.12%-13.96%-49.89%-43.44%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
NSPX
Inspyr Therapeutics
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
N/AN/AN/AN/AN/AN/AN/AN/A
Immune Pharmaceuticals, Inc. stock logo
IMNPQ
Immune Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
EOM Pharmaceuticals Holdings, Inc. stock logo
IMUC
EOM Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
N/AN/AN/AN/A
Immune Pharmaceuticals, Inc. stock logo
IMNPQ
Immune Pharmaceuticals
N/AN/AN/AN/A
EOM Pharmaceuticals Holdings, Inc. stock logo
IMUC
EOM Pharmaceuticals
N/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
$50K365.78N/AN/AN/A
Immune Pharmaceuticals, Inc. stock logo
IMNPQ
Immune Pharmaceuticals
N/AN/AN/AN/AN/AN/A
EOM Pharmaceuticals Holdings, Inc. stock logo
IMUC
EOM Pharmaceuticals
N/AN/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$23.99M0.00N/AN/A$0.05 per share0.00
NSPX
Inspyr Therapeutics
N/AN/AN/AN/A($0.07) per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
-$370KN/A0.00N/A5.77%20.61%11.73%N/A
Immune Pharmaceuticals, Inc. stock logo
IMNPQ
Immune Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/A
EOM Pharmaceuticals Holdings, Inc. stock logo
IMUC
EOM Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
-$8.28M-$4.16N/A0.00N/A-34.51%-682.54%-78.57%N/A
NSPX
Inspyr Therapeutics
-$6.30MN/A0.00N/AN/AN/AN/A-1,354.49%N/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
N/AN/AN/AN/AN/A
Immune Pharmaceuticals, Inc. stock logo
IMNPQ
Immune Pharmaceuticals
N/AN/AN/AN/AN/A
EOM Pharmaceuticals Holdings, Inc. stock logo
IMUC
EOM Pharmaceuticals
N/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
0.10
0.87
0.39
Immune Pharmaceuticals, Inc. stock logo
IMNPQ
Immune Pharmaceuticals
N/AN/AN/A
EOM Pharmaceuticals Holdings, Inc. stock logo
IMUC
EOM Pharmaceuticals
N/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/A
0.68
0.36
NSPX
Inspyr Therapeutics
N/A
0.09
0.09

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
8309.98 million232.80 millionNot Optionable
Immune Pharmaceuticals, Inc. stock logo
IMNPQ
Immune Pharmaceuticals
7N/AN/ANot Optionable
EOM Pharmaceuticals Holdings, Inc. stock logo
IMUC
EOM Pharmaceuticals
3N/AN/ANot Optionable
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
122.36 millionN/ANot Optionable
NSPX
Inspyr Therapeutics
1543.15 millionN/ANot Optionable

NSPX, ETST, IMUC, IMNPQ, and INNVD Headlines

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Earth Science Tech logo

Earth Science Tech

OTCMKTS:ETST
Earth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.
Immune Pharmaceuticals logo

Immune Pharmaceuticals

OTCMKTS:IMNPQ
Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is based in Fort Lee, New Jersey. On April 2, 2020, the voluntary petition of Immune Pharmaceuticals, Inc. along with its affiliates, for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on February 17, 2020.
EOM Pharmaceuticals logo

EOM Pharmaceuticals

OTCMKTS:IMUC
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.
Innovus Pharmaceuticals logo

Innovus Pharmaceuticals

OTCMKTS:INNVD
Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Inspyr Therapeutics

OTCMKTS:NSPX
Inspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.